Entrada Therapeutics, Inc.
TRDA
$8.15
-$0.18-2.16%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 210.78M | 215.23M | 239.40M | 162.87M | 129.01M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 210.78M | 215.23M | 239.40M | 162.87M | 129.01M |
| Cost of Revenue | 125.31M | 120.19M | 111.13M | 105.39M | 99.88M |
| Gross Profit | 85.48M | 95.04M | 128.27M | 57.48M | 29.13M |
| SG&A Expenses | 38.47M | 37.26M | 34.82M | 33.75M | 32.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 163.77M | 157.45M | 145.94M | 139.14M | 132.18M |
| Operating Income | 47.01M | 57.78M | 93.45M | 23.73M | -3.16M |
| Income Before Tax | 66.49M | 76.42M | 110.38M | 40.51M | 12.06M |
| Income Tax Expenses | 859.00K | 21.47M | 5.93M | 17.02M | 18.74M |
| Earnings from Continuing Operations | 65.63 | 54.95 | 104.44 | 23.49 | -6.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.63M | 54.95M | 104.44M | 23.49M | -6.69M |
| EBIT | 47.01M | 57.78M | 93.45M | 23.73M | -3.16M |
| EBITDA | 50.78M | 61.30M | 96.87M | 26.97M | -321.00K |
| EPS Basic | 1.99 | 1.68 | 3.09 | 0.70 | -0.21 |
| Normalized Basic EPS | 1.27 | 1.46 | 2.04 | 0.76 | 0.22 |
| EPS Diluted | 1.90 | 1.59 | 2.96 | 0.63 | -0.26 |
| Normalized Diluted EPS | 1.22 | 1.40 | 1.97 | 0.72 | 0.21 |
| Average Basic Shares Outstanding | 149.15M | 141.68M | 134.33M | 133.31M | 132.19M |
| Average Diluted Shares Outstanding | 153.98M | 144.30M | 138.44M | 136.10M | 133.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |